Dare Bioscience, Premier Research extend strategic partnership

Dare Bioscience and Premier Research International announced that the companies extended their partnership agreement under which Premier Research will continue to provide on an exclusive basis contract research organization, CRO, services within the United States to support the clinical development of Dare‘s reproductive health portfolio. The agreement was originally established with Health Decisions, Inc., which was acquired by Premier Research in 2021. “In 2020, Dare and Premier Research conducted a successful Phase 3 clinical study of XACIATO vaginal gel 2% despite the challenges posed by a global pandemic. As we approach the start of the pivotal clinical study of Ovaprene, we are excited to reaffirm our strategic partnership with Premier Research and leverage its deep expertise in the clinical development of women’s health products, including contraception,” said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. “Dare is committed to advancing a portfolio of differentiated product candidates that address meaningful unmet needs in women’s health in a timely and cost-efficient manner. This extended partnership has the potential to benefit multiple Dare programs, including those outside of reproductive health, such as the planned Phase 3 study of Sildenafil Cream, 3.6%, through the combination of commitment, clinical development expertise and cost savings.” Under the terms of the extended agreement, Premier Research will continue to be Dare’s exclusive provider of CRO services within the United States for all of Dare’s reproductive health product candidates for another three-year period. In exchange for that CRO exclusivity, Premier Research will continue to provide attractive pricing structures, clinical expertise, an extensive site network, relationships with key opinion leaders and investigators, and a core team of personnel dedicated to supporting all of Dare’s development programs covered by the agreement.